Author: admin

Refractory Metastatic Melanoma Pipeline Appears Robust With 4+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Refractory Metastatic Melanoma Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Refractory Metastatic Melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Refractory Metastatic Melanoma Research. Learn more about our innovative pipeline today! @ Refractory Metastatic Melanoma Pipeline Outlook

Key Takeaways from the Refractory Metastatic Melanoma Pipeline Report

  • In July 2025, Genmab announced clinical trial is to learn about the effectiveness and safety of the bispecific antibody acasunlimab (also known as DuoBody®-PD-L1x4-1BB) when given either alone or together with the cancer drug pembrolizumab in participants with locally advanced or metastatic melanoma of the skin. All participants will receive active drugs; no one will be given a placebo.
  • DelveInsight’s Refractory Metastatic Melanoma pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Refractory Metastatic Melanoma treatment.
  • The leading Refractory Metastatic Melanoma Companies such as BioNTech SE, Y-mAbs Therapeutics, Seagen Inc. and others.
  • Promising Refractory Metastatic Melanoma Pipeline Therapies such as GIM-531, Acasunlimab, Pembrolizumab, GSK2118436, GSK1120212, BNT111, Cemiplimab, BA3071, Nivolumab and others.

Stay informed about the cutting-edge advancements in Refractory Metastatic Melanoma treatments. Download for updates and be a part of the revolution in Dermatology care @ Refractory Metastatic Melanoma Clinical Trials Assessment

Refractory Metastatic Melanoma Emerging Drugs Profile

  • BNT111: BioNTech SE

BNT111 is an mRNA cancer vaccine candidate encoding a fixed set of four melanoma-associated antigens aiming to trigger a strong and precise immune response in patients with anti-PD-(L) 1 refractory/relapsed, unresectable Stage III or IV melanoma. BNT111 is an mRNA-based off-the-shelf cancer immunotherapy candidate for intravenous administration encoding a fixed set of four non-mutated melanoma-associated antigens (NY-ESO-1, MAGE-A3, tyrosinase, and TPTE) delivered as uridine mRNA-lipoplex formulation. Over 90% of patients with cutaneous melanomas express at least one of these antigens. The BNT111 program has also received Fast Track designation and Orphan Drug designation from the U.S. Food and Drug Administration. Currently, the drug is in Phase II stage of its development for the treatment of Refractory Metastatic Melanoma.

  • GD2-SADA: Y-mAbs Therapeutics

The GD2-SADA construct is created using SADA technology, that utilizes a pre-targeted payload delivery method where antibody constructs assemble in tetramers and bind to the tumor target. Unbound constructs predictably disassemble into smaller antibody fragments and are excreted through the kidneys within hours after administration. In a second infusion, a radioactive payload binds to the antibody constructs attached to the tumor target in order to radiate the tumor. This provides the possibility of targeting tumors with precision while minimizing radiation of normal tissues. The SADA technology platform can deliver a variety of payloads and could potentially be developed against multiple tumor targets, as well as for theragnostic purposes. Currently, the drug is in Phase I stage of its development for the treatment of Refractory Metastatic Melanoma.

The Refractory Metastatic Melanoma Pipeline Report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Refractory Metastatic Melanoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Refractory Metastatic Melanoma Treatment.
  • Refractory Metastatic Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Refractory Metastatic Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Refractory Metastatic Melanoma market.

Learn more about Refractory Metastatic Melanoma Drugs opportunities in our groundbreaking Refractory Metastatic Melanoma research and development projects @ Refractory Metastatic Melanoma Unmet Needs

Refractory Metastatic Melanoma Companies

BioNTech SE, Y-mAbs Therapeutics, Seagen Inc. and others.

Refractory Metastatic Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Refractory Metastatic Melanoma Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Discover the latest advancements in Refractory Metastatic Melanoma treatment by visiting our website. Stay informed about how we’re transforming the future of dermatology @ Refractory Metastatic Melanoma Market Drivers and Barriers, and Future Perspectives

Scope of the Refractory Metastatic Melanoma Pipeline Report

  • Coverage- Global
  • Refractory Metastatic Melanoma Companies- BioNTech SE, Y-mAbs Therapeutics, Seagen Inc. and others.
  • Refractory Metastatic Melanoma Pipeline Therapies- GIM-531, Acasunlimab, Pembrolizumab, GSK2118436, GSK1120212, BNT111, Cemiplimab, BA3071, Nivolumab and others.
  • Refractory Metastatic Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Refractory Metastatic Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Refractory Metastatic Melanoma Pipeline on our website @ Refractory Metastatic Melanoma Emerging Drugs and Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Refractory Metastatic Melanoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Refractory Metastatic Melanoma – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Refractory Metastatic Melanoma Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Drug Name: Company Name
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. BNT111: BioNTech SE
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. GD2-SADA: Y-mAbs Therapeutics
  17. Drug profiles in the detailed report…
  18. Pre-clinical and Discovery Stage Products
  19. Drug name: Company name
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Refractory Metastatic Melanoma Key Companies
  23. Refractory Metastatic Melanoma Key Products
  24. Refractory Metastatic Melanoma- Unmet Needs
  25. Refractory Metastatic Melanoma- Market Drivers and Barriers
  26. Refractory Metastatic Melanoma- Future Perspectives and Conclusion
  27. Refractory Metastatic Melanoma Analyst Views
  28. Refractory Metastatic Melanoma Key Companies
  29. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/refractory-metastatic-melanoma-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Refractory Metastatic Melanoma Pipeline Appears Robust With 4+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Crohn’s Disease Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Crohn’s Disease Pipeline Insight 2025” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Crohn’s Disease pipeline landscape. It covers the Crohn’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Crohn’s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Crohn’s Disease Treatment Landscape. Click here to read more @ Crohn’s Disease Pipeline Outlook

Key Takeaways from the Crohn’s Disease Pipeline Report

  • In July 2025, AbbVie conducted a study will evaluate the effectiveness and adverse events of targeted therapies (TaTs) for adult participants with moderate to severe CD. Crohn’s disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss. Treatments are available but do not work the same for all patients or may stop working over time.
  • In July 2025, Sanofi announced a study for the treatment of Crohn’s disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn’s disease. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants
  • In July 2025, Janssen Research & Development LLC organized a study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn’s Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.
  • In July 2025, Eli Lilly and Company announced a study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn’s disease.
  • DelveInsight’s Crohn’s Disease pipeline report depicts a robust space with 90+ active players working to develop 90+ pipeline therapies for Crohn’s Disease treatment.
  • The leading Crohn’s Disease companies such as Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, AbbVie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, SLA Pharma, HAV Vaccines Ltd, Enzo Biochem Inc., VHsquared Ltd., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Provention Bio, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Atlantic Healthcare, 4D Pharma, Landos Biopharma, Protagonist Therapeutics, Roche, Eisai, Bristol-Myers Squibb, Iltoo Pharma, Fast Forward Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Theravance Biopharma, TaiwanJ Pharmaceuticals, Active Biotech, Celularity, Cerecor, GlaxoSmithKline, Kang Stem Biotech, Alpha Cancer Technologies, Koutif Therapeutics, Winston Pharmaceuticals, Tract Therapeutics, Trio Medicines, Tetherex Pharmaceuticals, ChemoCentryx, Algernon Pharmaceuticals, Neuclone, Innovimmune Biotherapeutics, JHL Biotech, Intract Pharma Ltd, Innovative Pharmacological Research (IPHAR) Co Ltd, Innovation Pharmaceuticals, Exeliom Biosciences SAS, Finch Therapeutics, Akeso Biopharma, Draconis Pharma, MakScientific, Origo Biopharma, Navidea Biopharmaceuticals, Orchard Therapeutics, Xbrane, Thetis Pharmaceuticals, Temisis Therapeutics, Synedgen, Synlogic, PlantPraxis, Morphic Therapeutic, Metacrine, Curacle, Commence Bio Inc, Cloud Pharmaceuticals, Chong Kun Dang Pharmaceutical Corp, Avobis Bio LLC, Avexegen Therapeutics, Atlantic Bio Sci, Assembly Biosciences, Artelo Biosciences, Aibios Co Ltd, Aclaris Therapeutics, Athos Therapeutics, Denali Therapeutics, Educell doo and others.
  • Promising Crohn’s Disease Pipeline Therapies such as Etrasimod, Infliximab, MEDI2070, Filgotinib, Risankizumab 600 mg IV, CT-P13, and others.

Discover groundbreaking developments in Crohn’s Disease therapies! Gain in-depth knowledge of key Crohn’s Disease clinical trials, emerging drugs, and market opportunities @ Crohn’s Disease Clinical Trials Assessment

Crohn’s Disease Emerging Drugs Profile

  • Guselkumab: Janssen

Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation. In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological manifestations of psoriasis. It is currently in Phase III of clinical trial.

  • RHB-104: RedHill Biopharma

RHB-104 is a potentially groundbreaking, proprietary investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. It is currently in Phase III of clinical trial.

Crohn’s Disease Market Drivers

  • Increasing Prevalence of Inflammatory Bowel Disease
  • Development of New and Effective Therapies

Crohn’s Disease Market Barriers

  • Limited awareness and education
  • Failures and discontinuation of emerging therapies

The Crohn’s Disease Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Crohn’s Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Crohn’s Disease Treatment.
  • Crohn’s Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Crohn’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Crohn’s Disease market

Stay informed about the Crohn’s Disease pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Crohn’s Disease Unmet Needs

Crohn’s Disease Companies

Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, and others.

Crohn’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Crohn’s Disease Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Transform your understanding of the Crohn’s Disease Pipeline! See the latest progress in drug development and clinical research @ Crohn’s Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Crohn’s Disease Pipeline Report

  • Coverage- Global
  • Crohn’s Disease Companies- Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, and others.
  • Crohn’s Disease Pipeline Therapies- Etrasimod, Infliximab, MEDI2070, Filgotinib, Risankizumab 600 mg IV, CT-P13, and others.
  • Crohn’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Crohn’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

“Stay Ahead in Gastroenterology Research–Access the Full Crohn’s Disease Pipeline Analysis Today! @ Crohn’s Disease Drugs and Companies

Table of Content

  1. Introduction
  2. Crohn’s Disease Executive Summary
  3. Crohn’s Disease: Overview
  4. Crohn’s Disease Pipeline Therapeutics
  5. Crohn’s Disease Therapeutic Assessment
  6. Crohn’s Disease– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Ozanimod: Bristol-Myers Squibb
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. CBP-307: Suzhou Connect Biopharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. IMU-856: Immunic
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Crohn’s Disease Key Companies
  21. Crohn’s Disease Key Products
  22. Crohn’s Disease- Unmet Needs
  23. Crohn’s Disease- Market Drivers and Barriers
  24. Crohn’s Disease- Future Perspectives and Conclusion
  25. Crohn’s Disease Analyst Views
  26. Crohn’s Disease Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/crohns-disease-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Crohn’s Disease Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Psoriasis Pipeline Appears Robust With 65+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s “Psoriasis Pipeline Insight, 2025” report provides comprehensive insights about 65+ companies and 75+ pipeline drugs in the Psoriasis pipeline landscape. It covers the Psoriasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Psoriasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Psoriasis Research. Learn more about our innovative pipeline today! @ Psoriasis Pipeline Outlook

Key Takeaways from the Psoriasis Pipeline Report

  • In June 2025, Alumis Inc. announced a study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-001 twice daily for 24 weeks. After 24 weeks, the first 200 patients meeting at least PASI-75 clinical response will be randomly assigned to receive ESK-001 or placebo. At any point during this time, the patients losing the initial clinical response may return to the open-label ESK-001 treatment.
  • In June 2025, Soligenix conducted a study to evaluate SGX302 (topical hypericin ointment and gel) with visible light in an initial 18-week treatment course for improving lesions in patients with mild-to-moderate psoriasis.
  • In June 2025, Organon and Co. organized an open-label study in which participants will be assigned to receive VTAMA (tapinarof) cream, 1% once daily for 12 weeks. Study participants will have a follow-up period of 1 week. The study duration will be up to 17 weeks.
  • DelveInsight’s Psoriasis pipeline report depicts a robust space with 65+ active players working to develop 75+ pipeline therapies for Psoriasis treatment.
  • The leading Psoriasis Companies such as Can-Fite Biopharma, Huabo Biopharm Co., Ltd., MoonLake Immunotherapeutics, E-nitiate Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, BioRay Pharmaceutical Co., Ltd., SFA Therapeutics, Rubedo Life Sciences, Inc. and others.
  • Promising Psoriasis Pipeline Therapies such as Hypericin, EDP1815, Cetaphil, AX-158, HAT1 topical solution, Calcipotriol, ARQ-151 cream 0.3%, MP1032, Risankizumab, Certolizumab Pegol, and others.

Stay informed about the cutting-edge advancements in Psoriasis treatments. Download for updates and be a part of the revolution in Immunological and Autoimmune Disorders care @ Psoriasis Clinical Trials Assessment

Psoriasis Emerging Drugs Profile

  • Piclidenoson: Can-Fite Biopharma

Piclidenoson, generically known as IB-MECA (methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-b-D-ribofuronamide), is an oral small molecule drug formulated in a tablet. Piclidenoson mechanism of action is A3AR mediated and includes modulation of key signaling proteins, such as PI3K, PKA, PKB/Akt, IKK and NF-kB, resulting in de-regulation of the Wnt/β-catenin pathway and inhibition of inflammatory cytokine production. Currently, the drug is in Phase III stage of its development for the treatment of Psoriasis. 

  • Sonelokimab: MoonLake Immunotherapeutics

Sonelokimab is an investigational Nanobody® developed by MoonLake Immunotherapeutics for treating inflammatory diseases. It targets IL-17A and IL-17F cytokines, inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers, and includes a domain that binds to human albumin to enhance tissue penetration . In Phase 2 trials, sonelokimab demonstrated superior efficacy compared to AbbVie’s Humira in psoriatic arthritis, with higher percentages of patients achieving significant improvements in joint swelling and psoriasis severity . Additionally, it showed promising results in treating hidradenitis suppurativa, meeting the HiSCR75 endpoint in the Phase 2 MIRA trial. Currently, MoonLake is conducting Phase III trials for both conditions and exploring its use in other inflammatory diseases such as palmoplantar pustulosis and axial spondyloarthritis.

  • QY101: E-nitiate Biopharmaceuticals

QY101 is a topical ointment developed by E-nitiate Biopharmaceuticals for treating inflammatory skin conditions like atopic dermatitis and plaque psoriasis. It functions as a non-steroidal, non-hormonal phosphodiesterase 4 (PDE4) inhibitor, aiming to reduce inflammation by targeting overactive PDE4 pathways. Preclinical studies have demonstrated favorable pharmacokinetics, strong efficacy, and high safety, making it suitable for various age groups, including children. Currently, QY101 is undergoing a Phase II clinical trial in China for plaque psoriasis, following the completion of a Phase I trial in healthy volunteers. The company is also exploring additional formulations, such as an inhaler, through licensing collaborations.

  • SFA 002: SFA Therapeutics

SFA-002, an IL-10 up-regulator in immune cells, is approaching Phase 2 clinical trials and has shown promising Phase 1a and Phase Ib results for the treatment of psoriasis. SFA-002 met its primary endpoint of safety in the Phase 1b clinical trial. No treatment related adverse events or toxicities were observed during the treatment period, and no rebound effects were observed. SFA Therapeutics has filed its annual safety update with the U.S. Food and Drug Administration. SFA-002 met its exploratory endpoint of efficacy. Patients administered SFA-002 demonstrated statistically significant Psoriasis Area and Severity Index (PASI) percentage change and Investigator Global Assessment (IGA) score improvements compared to placebo. PASI is a tool used to measure the severity and extent of psoriasis while IGA is a standardized rating system of patient disease severity. The study was designed in two cohorts, to evaluate two different formulations. Currently the drug is in Phase II/III stage of its development for the treatment of Psoriasis.

  • RLS-1496: Rubedo Life Sciences, Inc

RLS-1496 is a first-in-class GPX4 modulator that targets aging cells and surrounding tissues being developed by Rubedo Life Sciences for the treatment of dermatological conditions and other chronic age-related diseases. It is a topical medicine designed to target aging cells, specifically senescent cells, in skin lesions of chronic atopic dermatitis and chronic psoriasis. Currently the drug is in Preclinical stage of its development for the treatment of Psoriasis.

The Psoriasis Pipeline Report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Psoriasis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Psoriasis Treatment.
  • Psoriasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Psoriasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Psoriasis market.

Learn more about Psoriasis Drugs opportunities in our groundbreaking Psoriasis research and development projects @ Psoriasis Unmet Needs

Psoriasis Companies

Can-Fite Biopharma, Huabo Biopharm Co., Ltd., MoonLake Immunotherapeutics, E-nitiate Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, BioRay Pharmaceutical Co., Ltd., SFA Therapeutics, Rubedo Life Sciences, Inc. and others.

Psoriasis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

Psoriasis Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

Discover the latest advancements in Psoriasis treatment by visiting our website. Stay informed about how we’re transforming the future of Immunological and Autoimmune Disorders @ Psoriasis Market Drivers and Barriers, and Future Perspectives

Scope of the Psoriasis Pipeline Report

  • Coverage- Global
  • Psoriasis Companies- Can-Fite Biopharma, Huabo Biopharm Co., Ltd., MoonLake Immunotherapeutics, E-nitiate Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, BioRay Pharmaceutical Co., Ltd., SFA Therapeutics, Rubedo Life Sciences, Inc. and others.
  • Psoriasis Pipeline Therapies- Hypericin, EDP1815, Cetaphil, AX-158, HAT1 topical solution, Calcipotriol, ARQ-151 cream 0.3%, MP1032, Risankizumab, Certolizumab Pegol, and others.
  • Psoriasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Psoriasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Psoriasis Pipeline on our website @ Psoriasis Emerging Drugs and Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Psoriasis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Psoriasis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Piclidenoson: Can-Fite Biopharma
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II/III)
  11. SFA 002: SFA Therapeutics
  12. Early Stage Products (Phase I/II)
  13. Drug Name: Company Name
  14. Drug profiles in the detailed report…..
  15. Preclinical and Discovery Stage Products
  16. RLS-1496: Rubedo Life Sciences, Inc
  17. Inactive Products
  18. Psoriasis Key Companies
  19. Psoriasis Key Products
  20. Psoriasis- Unmet Needs
  21. Psoriasis- Market Drivers and Barriers
  22. Psoriasis- Future Perspectives and Conclusion
  23. Psoriasis Analyst Views
  24. Psoriasis Key Companies
  25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/psoriasis-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Psoriasis Pipeline Appears Robust With 65+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Synovial Sarcoma Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Synovial Sarcoma Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Synovial Sarcoma pipeline landscape. It covers the Synovial Sarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Synovial Sarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Synovial Sarcoma Research. Learn more about our innovative pipeline today! @ Synovial Sarcoma Pipeline Outlook

Key Takeaways from the Synovial Sarcoma Pipeline Report

  • In June 2025, Adaptimmune announced a study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.
  • In June 2025, Epizyme Inc. conducted a study will include participants with various types of cancer known as soft-tissue sarcomas. Tissues that can be affected by soft tissue sarcomas include fat, muscle, blood vessels, deep skin tissues, tendons and ligaments. Soft tissue cancers are rare and can occur almost anywhere in the body.
  • DelveInsight’s Synovial Sarcoma pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Synovial Sarcoma treatment.
  • The leading Synovial Sarcoma Companies such as Advenchen Laboratories, Ipsen, OncoTherapy Science, C4 Therapeutics, Takara Bio, BioAtla, Inc., Immatics Biotechnologies GmbH, Sapience Therapeutics, PharmaMar and others.
  • Promising Synovial Sarcoma Pipeline Therapies such as TBI-1301, Cyclophosphamide, AL3818, Dacarbazine, Sorafenib and Dacarbazine, Soblidotin, Doxorubicin, APX005M, Pazopanib and others.

Stay informed about the cutting-edge advancements in Synovial Sarcoma treatments. Download for updates and be a part of the revolution in oncology care @ Synovial Sarcoma Clinical Trials Assessment

Synovial Sarcoma Emerging Drugs Profile

  • AL3818: Advenchen Laboratories

Anlotinib (AL3818) is a novel oral receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 and 3, fibroblast growth factor 1–4, platelet-derived growth factor receptor α and β, c-Kit and Ret. Anlotinib exerts inhibitory effects on tumor growth and angiogenesis. Anlotinib has encouraging efficacy and a manageable and tolerable safety profile in a broad range of malignancies, including medullary thyroid cancer, renal cell cancer, gastric cancer and esophageal squamous cell carcinoma. Currently, the drug is in the Phase III stage of its development for the treatment of Synovial sarcoma.

  • Tazemetostat: Ipsen

Tazemetostat is a first-in-class, oral small molecule inhibitor of the epigenetic enzyme EZH2. It is one of the histone methyltransferases in the epigenetics-related protein group, and is thought to regulate the expression of cancer-related genes and suppress the growth of cancer cells by specifically targeting EZH2, which contributes to the cancer growth process. Eisai holds the rights for development and commercialization of tazemetostat in Japan, where it was approved for the indication of “relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not applicable)” in 2021, and manufactures and distributes the product. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of synovial sarcoma.

  • DS-2243a: Daiichi Sankyo

DS-2243a is an investigational bispecific T-cell engager (BiTE) developed by Daiichi Sankyo, currently being studied for the treatment of advanced synovial sarcoma. This agent is designed to target tumors that express the HLA-A2 molecule and the cancer-testis antigen NY-ESO, both of which are commonly found in synovial sarcoma cells. By binding to both the tumor antigen and cytotoxic T lymphocytes, DS-2243a aims to direct the patient’s immune system specifically against synovial sarcoma cells, potentially improving the body’s ability to recognize and kill these cancerous cells. The ongoing Phase I clinical trial is focused on evaluating the safety, tolerability, and initial signs of efficacy of DS-2243a in patients with advanced synovial sarcoma who have limited treatment options.

The Synovial Sarcoma Pipeline Report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Synovial Sarcoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Synovial Sarcoma Treatment.
  • Synovial Sarcoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Synovial Sarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Synovial Sarcoma market.

Learn more about Synovial Sarcoma Drugs opportunities in our groundbreaking Synovial Sarcoma research and development projects @ Synovial Sarcoma Unmet Needs

Synovial Sarcoma Companies

Advenchen Laboratories, Ipsen, OncoTherapy Science, C4 Therapeutics, Takara Bio, BioAtla, Inc., Immatics Biotechnologies GmbH, Sapience Therapeutics, PharmaMar and others.

Synovial-Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Synovial Sarcoma Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Discover the latest advancements in Synovial Sarcoma treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Synovial Sarcoma Market Drivers and Barriers, and Future Perspectives

Scope of the Synovial Sarcoma Pipeline Report

  • Coverage- Global
  • Synovial Sarcoma Companies- Advenchen Laboratories, Ipsen, OncoTherapy Science, C4 Therapeutics, Takara Bio, BioAtla, Inc., Immatics Biotechnologies GmbH, Sapience Therapeutics, PharmaMar and others.
  • Synovial Sarcoma Pipeline Therapies- TBI-1301, Cyclophosphamide, AL3818, Dacarbazine, Sorafenib and Dacarbazine, Soblidotin, Doxorubicin, APX005M, Pazopanib and others.
  • Synovial Sarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Synovial Sarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Synovial Sarcoma Pipeline on our website @ Synovial Sarcoma Emerging Drugs and Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Synovial Sarcoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Synovial Sarcoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. AL3818: Advenchen Laboratories
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Tazemetostat: Ipsen
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. DS-2243a: Daiichi Sankyo
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Synovial Sarcoma Key Companies
  21. Synovial Sarcoma Key Products
  22. Synovial Sarcoma- Unmet Needs
  23. Synovial Sarcoma- Market Drivers and Barriers
  24. Synovial Sarcoma- Future Perspectives and Conclusion
  25. Synovial Sarcoma Analyst Views
  26. Synovial Sarcoma Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/synovial-sarcoma-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Synovial Sarcoma Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Streaming Analytics Market Advance Technology, Future Scope, Growing Trends, Outlook, Global Size, Share And Forecast – 2029

“IBM (US), Microsoft (US), Google (US), AWS (US), SAS Institute (US), SAP (Germany), Cloudera (US), Teradata (US), TIBCO (US), Software AG (Germany), Informatica (US), Intel (US), HPE (US), Adobe (US), Altair (US), Mphasis (India), Striim (US), Conviva (US), INETCO (Canada), WSO2 (US), Iguazio (Israel), Materialize (US), StarTree (US), Crosser (Sweden), Quix (UK), Lenses.io (UK).”
Streaming Analytics Market by Technology (Real-time Data Processing, Complex Event Processing, Data Visualization & Reporting, Event Stream Processing), Application (Fraud Detection, Predictive Asset Management, Risk Management) – Global Forecast to 2029.

The streaming analytics market is expected to expand at a compound annual growth rate (CAGR) of 33.6% from USD 29.53 billion in 2024 to USD 125.85 billion in 2029. Streaming analytics is the instantaneous processing and analysis of data as it flows continuously from various data sources. It includes using platforms and technology to get useful insights and quickly make data-driven decisions. The streaming analytics market’s rapid growth can be attributed to its capacity to process data quickly and facilitate prompt decision-making. Increased adoption of cloud-based solutions, advancements in data processing technologies, and the growing demand for real-time insights are all significant aspects in the streaming analytics industry.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64196229

By offering, the services segment to account for higher CAGR during the forecast period

The services segment in the streaming analytics market witnessed significant growth due to the rising adoption of real-time data processing by businesses. This increase is driven by the requirement for ongoing assistance, and specialist advice to enhance streaming analytics solutions and guarantee seamless performance. As organizations rely more on real-time data for making decisions, they require ongoing assistance to enhance the effectiveness of their analytics tools. This includes helping with implementation, system integration, performance optimization, and issue resolution. The growing demand for specialized services in response to the increasing complexity of data environments and the need for real-time insights is driving their rapid market expansion.

By application segment, fraud detection is expected to hold the largest market share during the forecast period

During the forecast period, fraud detection is expected to register the largest market share in the streaming analytics market. The ability of streaming analytics in processing and monitoring data in real time is fueled its dominance, as it is crucial for identifying and stopping fraudulent activities as it happen. Due to the growing digital transactions and more intricate fraud schemes, companies across various industries are utilizing advanced streaming analytics solutions to identify anomalies and safeguard financial transactions. As identifying fraud becomes more complex, the need for streaming analytics will play a key role in effectively identifying and stopping fraud.

By Vertical, healthcare & life sciences are projected to grow at the highest CAGR during the forecast period

The emergence of streaming analytics in the healthcare & life sciences industry has been groundbreaking, especially in improving patient care and operational effectiveness. The growing integration of IoT devices and streaming analytics enables healthcare providers to examine real-time data from medical devices. Streaming analytics solutions also help healthcare and life sciences industries by improving predictive care and encouraging proactive treatment approaches. Healthcare systems are capable of monitoring crucial indicators and notifying healthcare providers of any problems that are identified, triggering rapid clinical response. As healthcare data continues to grow, the use of streaming analytics will be crucial in enhancing services and developing personalized care options.

Asia Pacific is expected to grow at the highest CAGR during the forecast period

The Asia Pacific region is expected to see rapid growth in the streaming analytics market during the forecast period. The region’s swift digital evolution and growing use of technologies such as IoT and big data analytics are fueling the growth of the streaming analytics market. Countries in this region are making substantial investments in infrastructure and technological advancements which leads to an increasing need for real-time data processing and analytics solutions. Also, the increasing number of startups and the growth of sectors such as manufacturing, BFSI, and retail & ecommerce are fueling the growth of the streaming analytics market across the region.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=64196229

Unique Features in the Streaming Analytics Market

One of the most defining features of the streaming analytics market is its ability to process and analyze data in real-time. This is particularly valuable for organizations that rely on instant insights for decision-making, such as financial trading firms, e-commerce platforms, and logistics providers. Real-time analytics helps in detecting anomalies, monitoring events, and responding instantly to critical conditions.

Streaming analytics platforms are built to handle high-velocity data from various sources including IoT devices, mobile apps, and online transactions. These systems are designed to scale horizontally to accommodate increasing data loads without compromising processing speed. This scalability ensures uninterrupted data flow and analysis, even during peak demand.

The market offers platforms capable of ingesting data from diverse and heterogeneous sources such as sensors, logs, social media, applications, and databases. This ability to integrate structured, semi-structured, and unstructured data streams allows for a comprehensive and unified analytical view across the enterprise ecosystem.

Many solutions in the streaming analytics market are equipped with Complex Event Processing (CEP) capabilities. This allows businesses to detect specific patterns, trends, or sequences of events in real time. Such features are particularly useful in fraud detection, industrial automation, and predictive maintenance, enabling proactive interventions.

Major Highlights of the Streaming Analytics Market

Organizations across industries are increasingly prioritizing real-time data analytics to gain immediate insights and stay competitive. The demand for instant decision-making capabilities, especially in sectors like finance, retail, telecom, and manufacturing, is driving significant growth in the streaming analytics market.

The rapid proliferation of IoT devices has become a major driver for streaming analytics solutions. With sensors generating continuous data streams, there is a strong need to process and analyze this data at the edge to reduce latency and enhance responsiveness. This integration is fueling market adoption, particularly in smart cities, transportation, and industrial automation.

Businesses are increasingly leveraging AI and ML in streaming environments to enable predictive analytics and automated decision-making. The ability to embed ML models into streaming pipelines helps in uncovering patterns, forecasting trends, and executing real-time interventions, making analytics platforms more intelligent and proactive.

Cloud-native streaming analytics solutions are gaining momentum due to their scalability, flexibility, and cost-effectiveness. Enterprises are increasingly choosing cloud deployments to manage high volumes of streaming data without the burden of infrastructure maintenance, thus accelerating digital transformation efforts.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=64196229

Top Companies in the Streaming Analytics Market

The significant streaming analytics software and service providers include IBM (US), Microsoft (US), Google (US), AWS (US), SAS Institute (US), SAP (Germany), Cloudera (US), Teradata (US), TIBCO (US), Software AG (Germany), Informatica (US), Intel (US), HPE (US), Adobe (US), Altair (US), Mphasis (India), Striim (US), Conviva (US), INETCO (Canada), WSO2 (US), Iguazio (Israel), Materialize (US), StarTree (US), Crosser (Sweden), Quix (UK), Lenses.io (UK), BangDB (India), Imply (US), Coralogix (Israel), Ververica (Germany), KX (US), Confluent (US), Estuary (US), Fivetran (US), Hazelcast (US), DataStax (US), Solace (Canada), Databricks (US), GridGain Systems (US). These companies have used organic and inorganic growth strategies such as product launches, acquisitions, and partnerships to strengthen their position in the streaming analytics market.

Microsoft, a well-known international technology business that was founded in 1975 provides a wide range of products including cloud services software and hardware. With its main office in Redmond, Washington the business has operations in more than 190 nations. Microsoft Office Azure cloud computing platform and Windows operating system are some of its flagship products. Microsoft’s strategic priorities include AI cloud computing and productivity tools. The business caters to both enterprise and consumer markets. Microsoft offers robust streaming analytics solutions through its Azure cloud platform. Azure Stream Analytics is a real-time data processing service designed to analyze and visualize data streams from various sources, such as IoT devices, social media, and application logs. Azure Stream Analytics supports complex event processing and can handle large volumes of data with low latency. It is widely used across industries for monitoring, real-time decision-making, and operational intelligence.

Google, an Alphabet Inc. subsidiary has its headquarters located in Mountain View, California is a major player in the global technology and internet services industry. Google has had a great influence on the streaming analytics market due to its diverse range of tools and services. Google Cloud Platform provides strong options for handling and examining live data streams that helps organizations in efficiently handling large amounts of data. Thus, businesses can gain instant information, make quick decisions, and respond rapidly to changing conditions. Google’s infrastructure ensures that organizations of all sizes can easily make use of real-time analytics with the ability to grow and depend on it. Google is helping companies predict trends and promote innovation by using machine learning and advanced analytics, instead of only reacting to data.

AWS is a key player in the streaming analytics market, providing a variety of tools specifically built for managing real-time data processing on a large scale. AWS allows businesses to intake, handle, and examine data streams from different sources quickly using services such as Amazon Kinesis. These services are crucial in various applications such as real-time monitoring, fraud detection, supply chain management, and IoT data processing. Businesses can effectively obtain important data by leveraging AWS’s flexible infrastructure and varied analytics ecosystem, which also provides compatibility with AI/ML tools. AWS helps various businesses by enabling them to utilize real-time data for decision-making. AWS stands out in the streaming analytics market for its emphasis on innovation, security, and worldwide reach. This opportunity has enabled AWS to become a key player, offering enhanced operational efficiency and a competitive advantage to worldwide customers.

SAS Institute SAS Institute, commonly known as SAS, is an American multinational developer of analytics and artificial intelligence software headquartered in Cary, North Carolina. Founded in 1976 by Anthony James Barr, James Goodnight, John Sall, and Jane Helwig, the company originated from a project at North Carolina State University aimed at creating a statistical analysis system for agricultural research. Over time, SAS has evolved into a leading provider of analytics software, assisting organizations worldwide in accessing, managing, analyzing, and reporting data to support informed decision-making.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/streaming-analytics-market-64196229.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Streaming Analytics Market Advance Technology, Future Scope, Growing Trends, Outlook, Global Size, Share And Forecast – 2029

Cybersecurity Market Recent Technological Developments, Growth Demand, Opportunities, Future Scope, Key Segments And Forecast To 2030

“IBM (US), Cisco (US), Microsoft (US), Palo Alto Networks (US), Fortinet (US), Check Point (Israel), Trellix (US), Trend Micro (Japan), Rapid7 (US), Google (US), Cloudflare (US), Proofpoint (US), F5 (US), Gen Digital (US), CrowdStrike (US), CY4GATE (Italy), Broadcom (US), SentinelOne (US), OpenText (Canada), Accenture (Ireland), CyberArk (US), Zscaler (US), NETSCOUT (US), Dell Technologies (US), Netskope (US), Okta (US).”
Cybersecurity Market by Solution Type (IAM, Firewall & VPN, Log Management & SIEM, Antivirus/Antimalware), Service (Professional (Risk & Threat Assessment, Training & Education), Managed), Security Type (Cloud, Application) – Global Forecast to 2030.

The size of the worldwide cybersecurity market is expected to increase at a Compound Annual Growth Rate (CAGR) of 9.1% from USD 227.59 billion in 2025 to USD 351.92 billion by 2030. The increasing use of Cybersecurity Mesh Architecture (CSMA), which permits a more adaptable and modular strategy to safeguarding increasingly dispersed IT environments, is propelling the cybersecurity market. By facilitating smooth integration across security tools and systems, CSMA improves identity management, threat detection, and response coordination. At the same time, companies are being forced to invest in cutting-edge security measures to protect their vital corporate assets due to the increasing frequency and sophistication of cyberattacks. Businesses are giving end-to-end protection plans top priority in order to guarantee resilience and continuity against changing threats as a result of the expansion of attack surfaces brought about by digital transformation.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=505

Based on solution type, the log management & SIEM segment is expected to hold the largest market share during the forecast period.

The log management & SIEM segment is mainly fueled by the increasing complexity of the IT infrastructure and the explosive growth of security data generated by devices, applications, and clouds. Enterprises heavily invest in SIEM systems to normalize log accumulation, achieve regulatory conformity, and identify advanced threats using real-time correlation and analytics. With the machine learning integrated modern SIEM tools, security teams are automating the process of alerting and investigation, significantly decreasing dwell time. The growing ransomware attacks, malicious insiders, and advanced persistent threats (APTs) have only expedited the need for SIEM solutions with enhanced threat intelligence and behavioral analytics. More recent developments focus on bringing Security Orchestration, Automation, and Response (SOAR) capabilities to SIEM to support quicker remediation. Strict compliance requirements are especially making the segment popular among industries such as BFSI, healthcare, and government.

By security type, the network security segment accounts for the largest market share during the forecast period.

Network security is the largest segment of the cybersecurity market because enterprises are more interested in real-time protection of their distributed and hybrid infrastructures. Edge computing, remote work, and cloud-hosted applications have significantly increased the attack surface area, requiring a high-level network-based defense. Organizations are focusing more on the implementation of next-generation firewalls (NGFWs), intrusion detection and prevention systems (IDS/IPS), network access control (NAC), and secure web gateways to protect internal as well as external traffic. The current trends of adopting Zero Trust Network Access (ZTNA) and Secure Access Service Edge (SASE) architectures signify a move toward more dynamic and identity-based controls over traffic. Telecommunication companies and other extensive IT corporations are improving their network security systems to protect themselves against increased DDoS attacks and supply chain risks. Moreover, the escalation of geopolitical tensions and the use of state resources to launch cyberattacks have made governments and the owners of critical infrastructure invest significant funds in improving their network security postures on-premises and in cloud environments.

By region, Asia Pacific is expected to grow at the highest CAGR during the forecast period.

The cybersecurity market in Asia Pacific is growing at the fastest rate, driven by the high rate of digital transformation, the sophistication of cyberattacks, and the escalating focus on national cybersecurity policies. India, China, Japan, and Australia are some countries that are extensively investing in cybersecurity systems to accommodate the growth of digital economies and the defense of critical infrastructures. Ransomware and phishing attacks are increasing drastically in the region, especially in the BFSI, health care, and manufacturing sectors. With the development of 5G deployment and innovative city projects, secure scale and effective security solutions are soaring. The regulatory trends, such as the Digital Personal Data Protection Act in India and the stricter data localization regulations in China, force organizations to spend on data security, identity access management, and endpoint protection. Global vendors, such as Palo Alto Networks, Fortinet, CrowdStrike, Trend Micro, and Check Point, are establishing their presence in the region by opening regional offices, partnering, and offering managed security services. Regulatory pressure drives investment in IAM, endpoint protection, and cloud security, including the Digital Personal Data Protection Act in India and data security regulations in China. The increase in the establishment of cybersecurity centers and regional threat intelligence centers further enhances the cyber defense position in the region.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=505

Unique Features in the Cybersecurity Market

One of the most defining features of the cybersecurity market today is the integration of artificial intelligence (AI) and machine learning (ML). These technologies enhance threat detection by analyzing patterns in real-time, identifying anomalies, and predicting potential breaches before they occur. This proactive defense mechanism reduces response times and improves the accuracy of threat identification.

Zero Trust has become a cornerstone of modern cybersecurity. Unlike traditional models that assume trust within the network, Zero Trust mandates verification of every user and device trying to access resources, regardless of their location. This shift greatly minimizes the risk of insider threats and lateral movement within compromised systems.

As businesses migrate to the cloud, the cybersecurity market has evolved to offer cloud-native solutions. These are designed to secure multi-cloud and hybrid environments with tools like Cloud Access Security Brokers (CASBs), container security, and cloud workload protection platforms (CWPPs), ensuring scalable and agile defense systems.

XDR platforms are gaining traction as they unify multiple security products into a cohesive threat detection and incident response system. Unlike isolated tools, XDR offers end-to-end visibility across endpoints, networks, servers, and cloud workloads, streamlining investigation and remediation processes.

Major Highlights of the Cybersecurity Market

The cybersecurity market is experiencing unprecedented growth driven by the increasing volume and sophistication of cyber threats. From ransomware and phishing attacks to nation-state hacking and advanced persistent threats (APTs), organizations across all sectors are investing heavily in security infrastructure to protect their digital assets.

Traditional reactive security approaches are being replaced with proactive, predictive models. Organizations are now leveraging technologies such as threat intelligence, AI-driven analytics, and behavioral monitoring to anticipate and neutralize threats before they cause damage.

The widespread adoption of cloud computing and hybrid/remote work models has accelerated demand for cloud-centric security solutions. Businesses are investing in Secure Access Service Edge (SASE), Zero Trust Network Access (ZTNA), and identity management tools to secure remote endpoints and cloud environments.

Increasing global regulatory scrutiny is prompting companies to prioritize cybersecurity compliance. Regulations like GDPR, HIPAA, PCI-DSS, and CCPA are pushing organizations to adopt stringent data protection policies and invest in compliance-oriented cybersecurity tools and audits.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=505

Top Companies in the Cybersecurity Market

The cybersecurity market is led by some of the globally established players, such as IBM (US), Cisco (US), Microsoft (US), Palo Alto Networks (US), Fortinet (US), Check Point (Israel), Trellix (US), Trend Micro (Japan), Rapid7 (US), Google (US), Cloudflare (US), Proofpoint (US), F5 (US), Gen Digital (US), CrowdStrike (US), CY4GATE (Italy), Broadcom (US), SentinelOne (US), OpenText (Canada), Accenture (Ireland), CyberArk (US), Zscaler (US), NETSCOUT (US), Dell Technologies (US), Netskope (US), and Okta (US). The market players have adopted various strategies, such as developing advanced products, partnerships, contracts, expansions, and acquisitions, to strengthen their position in the cybersecurity market. Organic and inorganic strategies have helped the market players expand globally by providing advanced cybersecurity solutions.

Rapid7 is a leading provider of advanced cybersecurity analytics, vulnerability management, and threat detection solutions, supporting organizations across industries in safeguarding their digital environments. Through its integrated cloud-native platform and extensive threat intelligence, Rapid7 empowers security teams to identify, prioritize, and remediate vulnerabilities efficiently. The company delivers a comprehensive portfolio of solutions covering threat exposure management, incident detection and response, cloud security, and automation. With cyber threats growing more complex and attack surfaces expanding, Rapid7’s unified platform, featuring products such as InsightVM, InsightIDR, and InsightConnect, enables organizations to achieve real-time visibility and streamlined security operations. Its solutions help reduce risk exposure by correlating telemetry across endpoints, networks, and cloud workloads while minimizing false positives and enhancing team productivity. Rapid7 continues to drive innovation through automation, data-driven insights, and community collaboration, ensuring its platform evolves in alignment with zero-trust strategies, regulatory demands, and the rising sophistication of cyber adversaries.

SentinelOne is a leading provider of autonomous cybersecurity solutions, offering integrated endpoint, cloud, and identity protection powered by artificial intelligence and machine learning. The company’s Singularity platform enables real-time threat prevention, detection, response, and remediation across diverse digital environments, allowing organizations to defend against increasingly sophisticated cyberattacks. With a focus on automation and scalability, SentinelOne delivers behavior-based protection that eliminates the need for human-dependent detection, minimizing dwell time and enhancing response efficiency. Its AI-driven approach empowers security teams to proactively hunt threats, orchestrate incident response, and achieve operational resilience. The platform’s seamless integration with third-party tools and native XDR capabilities ensures holistic visibility and control over endpoints, cloud workloads, and identity systems. As cyber threats continue to evolve, SentinelOne advances its technology through continuous innovation, research-led intelligence, and global threat telemetry, helping enterprises meet compliance mandates, adopt zero-trust models, and secure their digital transformation initiatives with confidence.

IBM (US) is a global leader in the cybersecurity market, offering a comprehensive range of solutions and services to protect organizations across industries from evolving cyber threats. Through its IBM Security division, the company provides advanced tools for threat intelligence, identity and access management, data protection, cloud security, and incident response. IBM’s flagship offerings include QRadar for security information and event management (SIEM), Guardium for data security, and X-Force for threat intelligence and managed services. Leveraging AI, automation, and deep analytics, IBM helps enterprises enhance their cyber resilience and comply with complex regulatory requirements.

Cisco (US) is a major player in the cybersecurity market, delivering a wide array of integrated security solutions that protect networks, endpoints, cloud environments, and applications. Known for its strength in networking, Cisco leverages its infrastructure expertise to offer robust cybersecurity products such as Cisco Secure Firewall, Umbrella (cloud security), Duo (zero trust and multi-factor authentication), and SecureX (security operations platform). Cisco focuses on threat detection, secure access, and automation to provide end-to-end protection for enterprises of all sizes, helping organizations defend against advanced threats while maintaining visibility and control across their IT environments.

Microsoft (US) is a leading force in the cybersecurity market, offering a broad and deeply integrated suite of security solutions across cloud, endpoint, identity, and data. With its Microsoft Security portfolio, including Microsoft Defender, Sentinel (SIEM/SOAR), Entra (identity and access management), and Purview (data protection), the company delivers AI-powered threat detection, response, and compliance tools. Microsoft secures its vast ecosystem—from Windows and Azure to Microsoft 365—helping organizations of all sizes enhance their security posture. Its global threat intelligence, combined with strong investments in research and automation, positions Microsoft as a key partner in defending against sophisticated cyber threats.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/cyber-security-market-505.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cybersecurity Market Recent Technological Developments, Growth Demand, Opportunities, Future Scope, Key Segments And Forecast To 2030

Global Plant-based Protein Market Forecast, Emerging Trends, Drivers, Top Companies, and Growth Outlook (2025-2030)

“MarketsandMarkets™”
Plant-based Protein Market by Source (Soy, Wheat, Pea, Canola, Rice, & Potato, Faba Beans), Type (Concentrates, Isolates, Textured, Milled Protein Flours, Strach-rich Protein Flours), Application, Nature, Form, Function, and Region – Global Forecast to 2030

The plant-based protein market is estimated at USD 23.89 billion in 2025 and is projected to reach USD 34.97 billion by 2030, at a CAGR of 7.9% from 2025 to 2030. Plant-based proteins are expected to witness significant demand in the coming years due to the increase in veganism and flexitarian diets and the increasing requirement for plant-based meat and dairy alternatives. In recent years, plant-based protein has become popular due to its high nutritional value, which includes a complete protein profile, high digestibility, and a balanced amino acid composition. Plant-based protein from various sources meets adequate caloric and essential nutrient requirements. Pea protein and other emerging sources of plant-based protein have experienced immense popularity in recent years. This trend is expected to persist during the forecast period due to the growing number of individuals seeking alternatives to soy-based proteins because of the increasing prevalence of soy allergies and other causes of soy intolerance.

Plant-based Protein Market

 

Plant-based Protein Market Growth Drivers

  • Health & Wellness Trends: Consumers are actively seeking high-protein, low-fat, and cholesterol-free options. Plant-based proteins offer essential amino acids and are linked to a lower risk of chronic diseases such as heart disease and obesity.
  • Environmental Sustainability: The production of plant-based proteins requires fewer natural resources—less water, land, and energy—compared to animal agriculture. As climate change awareness rises, so does the preference for environmentally responsible food choices.
  • Vegan & Flexitarian Lifestyles: The rise of vegan, vegetarian, and flexitarian diets is reshaping food consumption patterns. People are not only avoiding meat for ethical reasons but also incorporating more plant-based meals for variety and balance.
  • Food Tech Innovation: Advances in food processing and biotechnology are enhancing the taste, texture, and nutritional profile of plant-based protein products, closing the sensory gap with meat and dairy alternatives.
  • Expanding Product Applications: Plant-based proteins are now found in everything from meat substitutes and dairy alternatives to snacks, beverages, baked goods, and sports nutrition products.

 

Emerging Trends in the Plant-based Protein Market

  • Clean Label and Natural Ingredients: There is a growing demand for products with minimal processing and recognizable ingredients. Clean label certifications are becoming a key differentiator.
  • Novel Protein Sources: Beyond traditional sources like soy and peas, new plant proteins such as hemp, quinoa, algae, and pulses are being explored to diversify the market.
  • Hybrid and Blended Products: Combining plant proteins with other ingredients to create hybrid products is gaining popularity, offering improved nutritional profiles and consumer acceptance.
  • Functional and Sports Nutrition: Plant-based proteins are increasingly used in supplements and functional foods, targeting athletes and health-conscious consumers.
  • Expansion in Foodservice: Partnerships with restaurants and foodservice chains are making plant-based protein options more accessible and mainstream.

 

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=14715651

Milled protein flour is projected to grow at a significant rate during forecast period

Milled protein flours are experiencing significant growth in the plant-based protein market due to their versatility and high nutritional value, catering to the rising demand for plant-based diets. Derived from soy, peas, lentils, and chickpeas, these flours are finely milled to enhance protein content, making them ideal for applications in bakery, snacks, and meat analogs. Their ability to improve texture and nutritional profiles in products drives their popularity, particularly among health-conscious consumers.

The conventional plant-based proteins segment will hold largest market share during forecast period.

Plant-based protein ingredients are conventional and organic. Conventional plant-based protein, sourced from soy, wheat, pea, chickpeas, and others, is extensively used across food and beverage applications, including bakery products, snacks, and meat alternatives. Manufacturers prefer conventional options due to their flexibility in large-scale sourcing and processing without stringent organic compliance requirements. In recent years, more and more consumers have been shifting away from animal-based protein sources and opting for plant-based foods instead. This has led to a surge in demand for plant-based protein products. It is important to highlight that conventional crops usually have slightly higher protein levels than organic crops. This is often due to the use of fertilizers, pesticides, and other synthetic chemicals in conventional farming practices. As a result, traditional plant-based protein sources may be better equipped to meet the increasing demand for plant-based protein products.

The European region is to hold a significant market share during the forecast period.

The European market presents significant business opportunities for manufacturers of plant-based protein ingredients. Veganism has grown exponentially in the country and now represents a considerable share of the population. Key factors encouraging this change include increasing concerns over sustainability and a high prospect of good health practices. While veganism remains a prominent trend in the consumer market, it has greatly impacted the industrial sector, leading to changes in its product offerings and the processing requirements addressed. This increasing trend of adopting veganism and shifting away from animal meat has presented significant business opportunities for companies operating in the plant-based protein industry.

Leading Plant-based Protein Companies:

The report profiles key players such as Cargill, Incorporated (US), ADM (US), Kerry Group PLC (Ireland), International Flavors & Fragrances Inc. (US), Ingredion Incorporated (US), Wilmar International Ltd. (Singapore), Roquette Frères (France), Glanbia PLC (Ireland), DSM-Firmenich (Switzerland), AGT Food and Ingredients (Canada), Tate & Lyle (UK), Burcon (Canada), Emsland Group (Germany), PURIS (US), and COSUCRA (Belgium).

Recent Developments in the Plant-based Protein Industry:

  • In November 2024, Ingredion Incorporated (US) and Lantmännen formed a strategic partnership to advance plant-based proteins, focusing on sustainably sourced yellow pea protein isolates. Lantmännen will invest over USD 108.2 million (€100 million) in a new Swedish facility, while Ingredion brings expertise in product development and market access, targeting Europe’s fast-growing alternative protein sector.
  • In November 2024, Burcon (Canada) partnered with Puratos to develop innovative canola protein applications for the bakery and patisserie sectors. Leveraging Burcon’s Puratein canola protein and Puratos’s global R&D expertise, the collaboration aims to deliver healthier, sustainable, and cost-effective alternatives to traditional ingredients such as eggs.
  • In November 2024, BENEO (Germany) showcased scalable plant-based and hybrid solutions using texturates from meatless and faba bean protein concentrates at Fi Europe to accelerate product development. By covering ingredient formulation to final products, BENEO helps manufacturers reduce costs and time-to-market while maintaining quality, taste, and texture for evolving consumer preferences.
  • In February 2024, Roquette Frères (France) expanded its NURRALYS plant protein portfolio by introducing four new pea protein ingredients, including isolates, hydrolysates, and textured variants. These multi-functional pea proteins are designed to address formulation challenges in plant-based foods and high-protein nutritional products, offering opportunities for innovation in applications such as nutritional bars, protein drinks, and plant-based meat and dairy alternatives.

 

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=14715651

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/plant-based-protein-market-14715651.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Global Plant-based Protein Market Forecast, Emerging Trends, Drivers, Top Companies, and Growth Outlook (2025-2030)

Strobilurin Market Outlook 2025-2030: Trends, Growth Drivers & Forecasts

“MarketsandMarkets™”
Strobilurin Market by Product Type (Azoxystrobin, Pyraclostrobin, Trifloxystrobin, Kresoxim-Methyl, Picoxystrobin, Fluoxastrobin, Others), Crop Type (Cereals & Grains, Fruits & Vegetables, Oilseeds & Pulses, Turf & Ornamentals, Others), Formulation Type (Liquid, Dry, Granular), Application Method (Foliar Spray, Soil Treatment, Seed Treatment, Others), and Region – Global Forecast to 2030

The strobilurin market is projected to expand from USD 5.53 billion in 2025 to USD 6.88 billion by 2030, at a CAGR of 4.47% during the forecast period. The market is witnessing robust growth, driven by rising global food demand, increasing incidences of crop diseases, and the need for higher agricultural productivity. Farmers are increasingly adopting strobilurin-based fungicides due to their broad-spectrum disease control, yield enhancement properties, and systemic action. A key trend in the market is the development of combination products that integrate strobilurin with other active ingredients to improve efficacy and manage resistance. Additionally, growing demand from developing countries, government support for crop protection practices, and the expansion of high-value crop cultivation are fueling market growth.

Strobilurin Market

 

Strobilurin Market Drivers

  • Rising Global Food Demand: Increasing population and changing dietary patterns are pushing agricultural productivity, thereby boosting the demand for efficient fungicides like strobilurins.
  • Crop Yield and Quality Enhancement: Strobilurins not only control fungal diseases but also exhibit physiological benefits such as improved photosynthesis and delayed senescence, contributing to higher yields and better crop quality.
  • Expansion of High-Value Crops: As farmers increasingly grow high-value crops (like grapes, strawberries, and tomatoes), the need for effective disease control with strobilurin-based fungicides is expanding.
  • Integrated Pest Management (IPM) Programs: Strobilurins fit well into IPM strategies due to their low toxicity to non-target organisms, supporting sustainable agriculture practices.

 

Future Trends of Strobilurin Market

  • Biological Integration: Companies are exploring bio-stimulant and bio-fungicide combinations to extend the efficacy of strobilurins.
  • Formulation Innovation: Nano-formulations and controlled-release technologies are enhancing product performance.
  • Digital Agriculture: AI and drone-based spraying technologies are improving fungicide application efficiency.

 

By product type, the azoxystrobin segment holds a significant market share in the global strobilurin market.

In the strobilurin market, azoxystrobin holds the largest share within the product type segment, primarily due to its wide applicability, high efficacy, and plant health benefits beyond disease control. As a broad-spectrum fungicide, azoxystrobin is used extensively across various high-value crops such as cereals, fruits, vegetables, grapes, and soybeans, providing effective protection against key fungal diseases including rusts, powdery mildew, downy mildew, and leaf spots. Its systemic and translaminar movement within plants ensures long-lasting protection, which enhances its popularity among growers. Moreover, azoxystrobin contributes to enhanced photosynthetic activity, delayed senescence, and overall yield improvement, making it a favorable choice in both preventive and curative fungicide programs. With strong regulatory approvals across major agricultural economies and rising awareness among farmers about its yield-boosting properties, azoxystrobin continues to lead the strobilurin market globally.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=108903839

By application method, the foliar spray segment holds a significant market share in the strobilurin market.

By application method, foliar spray holds the largest share in the strobilurin market, driven by its effectiveness in delivering quick and uniform coverage to crops. Foliar spraying allows the fungicide to be directly applied to the leaves, where most fungal infections occur, ensuring rapid absorption and immediate protective or curative action. This method enhances the fungicide’s efficacy by optimizing contact with the target pathogens, thereby improving disease control and minimizing crop damage. Additionally, foliar sprays are easy to apply using standard agricultural equipment, making them suitable for large-scale farming operations across diverse crop types. The growing demand for efficient and cost-effective crop protection solutions, along with the increasing cultivation of fruits, vegetables, and cereals that benefit from foliar application, continues to support the dominance of this segment in the market.

Europe is estimated to hold the largest market share in the strobilurin market.

Europe holds the largest share in the strobilurin market, primarily due to the region’s advanced agricultural practices, high awareness of crop protection, and strong regulatory framework supporting the use of effective fungicides. Countries like France, Germany, Spain, and Italy have extensive cultivation of cereals, fruits, and vegetables, which are highly susceptible to fungal diseases and thus demand preventive solutions such as strobilurins. The region’s focus on achieving high crop yields and quality, coupled with widespread adoption of integrated pest management (IPM) strategies, further drives the use of strobilurin-based products. Moreover, continuous product innovation, favorable government support for sustainable farming, and the presence of leading agrochemical manufacturers contribute to Europe’s dominant position in the global market.

Leading Strobilurin Companies:

The report profiles key players such as BASF (Germany), Bayer Group (Germany), Corteva (US), Syngenta (Switzerland), FMC Corporation (US), UPL (India), Sumitomo Chemical Co., Ltd. (Japan), Nufarm Limited (Australia), AMVAC Chemical Corporation (US), Gowan Company, LLC (US), Albaugh, LLC (US), Limin Group Co., Ltd. (China), Hailir Pesticides and Chemicals Group (China), Coromandel International Limited (India), and Adama Agricultural Solutions Ltd. (Israel).

Recent Developments in the Strobilurin Industry:

  • In May 2025, Syngenta’s new biologicals facility in South Carolina will have the potential to enhance innovation and the company’s overall production capabilities. This reinforces Syngenta’s crop solutions portfolio and develops its position in the US strobilurins competitive landscape.
  • In May 2025, Syngenta’s Strobilurin fungicide, Metcyclofenstrobin, received provisional ISO approval, adding to Syngenta’s Strobilurin fungicide portfolio. This innovation not only delivers broad-spectrum activity while extending lasting control, protected by patent until 2040, but it also enhances Syngenta’s global Strobilurin position by adding a new advanced system for farmers to manage key fungal diseases in cereals, vegetables, and specialty crops.
  • In May 2025, Corteva announced a major USD 27.5 million expansion facility in Midland. It will increase R&D capacity and further enhance its crop protection technology innovation (including strobilurin fungicides) to strengthen market competitiveness and provide agricultural solutions that promote sustainability.
  • In June 2024, Sumitomo Chemical achieved provisional ISO certification for the innovative strobilurin fungicide, bifemetstrobin, which delivers broad-spectrum disease control. This innovative fungicide advances Sumitomo’s competitive position in the global strobilurin fungicide category, adding another (patented) solution to the portfolio to use against core commodities such as rice, wheat, corn, and canola.

 

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=108903839

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/strobilurin-fungicide-market-108903839.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Strobilurin Market Outlook 2025-2030: Trends, Growth Drivers & Forecasts

Probiotics in Animal Feed Market Size, Share, Growth Drivers, Opportunities, and Forecast Report (2025–2030)

“MarketsandMarkets™”
Probiotics in Animal Feed Market by Source (Bacteria, Yeast & Fungi), Livestock (Poultry, Swine, Ruminants, Aquaculture, Pet, and Other Livestock), Form (Liquid, Dry), Strain Specificity, Function, Distribution Channel, and Region – Global Forecast to 2030

The probiotics in animal feed market is projected to expand from USD 5.40 billion in 2025 to USD 8.27 billion by 2030, at a CAGR of 8.9% during the forecast period. The global market has been growing steadily, fueled by increasing awareness of animal health and welfare, as well as a global shift toward reducing antibiotic use in livestock production. Producers are turning to probiotics to enhance feed efficiency, boost immunity, and support the overall well-being of animals, responding to both regulatory pressures and consumer demand for safer, more sustainable animal products. Advances in biotechnology have enabled the development of more effective, species-specific probiotic formulations, further driving their adoption across poultry, swine, cattle, and aquaculture sectors. This trend is expected to persist as the industry continues to prioritize natural feed additives and sustainable farming practices.

Probiotics in Animal Feed Market

 

Probiotics in Animal Feed Market Growth Drivers:

  • Ban on Antibiotic Growth Promoters (AGPs): Regulatory actions in regions such as the EU and parts of Asia have restricted or banned the use of AGPs in animal feed, encouraging the adoption of natural alternatives like probiotics.
  • Rising Demand for Protein-Rich Diets: The global surge in meat and dairy consumption is pressuring livestock producers to improve productivity, making probiotics a valuable tool for enhancing feed efficiency and growth rates.
  • Gut Health and Immunity Benefits: Probiotics help maintain a balanced gut microbiota, improve nutrient absorption, and reduce the risk of infections, leading to healthier animals and lower mortality rates.
  • Sustainability and Animal Welfare Trends: With consumers increasingly concerned about sustainable farming practices, probiotics offer a way to produce healthier animals without synthetic additives.

 

Probiotics in Animal Feed Market Opportunities: Increasing demand in developing countries due to the growing livestock sector

The livestock sector within developing nations is ever-expanding and growing particularly fast in segments such as poultry, swine, and dairy, therefore increasing feed probiotics demand. Additionally, as animal farming is intensifying in countries such as China, India, and Vietnam, the emphasis on improving animal health, productivity, and sustainability—the major elements influencing probiotic adoption in feed formulations—is stronger than ever. Probiotics are essential for improving gut health, immunity, and nutrient absorption in animal production, which is significant in developing countries as they strive for food production on a large-scale basis while managing the reduction of antibiotic usage.

With a combined total of 230.58 million tonnes of milk produced in 2022-23, an increase of 3.83% from the previous year, India’s Department of Animal Husbandry and Dairying (2023-24) reports further growth in animal care by producing 8.90% more cow milk in 2020 and working towards even more significant production increases in future years. In 2023, the USDA reported China’s beef production to grow by 2.7% in 2024 to reach 7.7 million tonnes, demonstrating a growing global understanding of the need for probiotics in livestock systems to support higher productivity and health outcomes.

By source, the bacterial source of probiotics holds a significant market share in the global probiotics in animal feed market.

Bacteria-based probiotics are dominating the animal feed market, primarily due to their extensive research history, proven effectiveness, and commercial availability. Bacterial strains such as Lactobacillus, Bacillus, Streptococcus, and Bifidobacterium are widely used because they offer superior benefits for animal gut health, nutrient absorption, and immune system support compared to other sources like yeast or fungi. Their better resistance to bile acids ensures they reach the intestine and colon, where they exert the most beneficial effects. Additionally, bacterial probiotics are generally more cost-effective and accessible, making them the preferred choice among producers. The favorable regulatory environment and ongoing advancements in bacterial probiotic formulations further reinforce their leading position in the animal feed industry.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=85832335

By livestock, poultry constitutes a significant market share in the probiotics in animal feed market.

The poultry segment holds a major share in the probiotics in animal feed market, driven by the extensive use of probiotics to enhance growth rates, feed conversion efficiency, and overall flock health. Poultry producers are increasingly adopting probiotics as natural alternatives to antibiotics, responding to both regulatory restrictions and consumer demand for antibiotic-free, high-quality meat and eggs. The dominance of poultry is further supported by the rapid expansion of commercial poultry farming worldwide and the high demand for protein-rich diets, particularly in regions like the Asia Pacific, where poultry production is substantial. These factors collectively ensure that poultry remains the leading livestock segment in the adoption of probiotics for animal nutrition.

Asia Pacific is estimated to hold the largest market share in the probiotics in animal feed market.

Asia Pacific holds the largest share of the probiotics in animal feed market, driven by its vast livestock population, rapid industrialization of animal farming, and increasing awareness of animal health and productivity benefits associated with probiotics. Countries like China, India, and Japan are major contributors, with China leading due to its substantial feed production and large-scale poultry and swine industries. The region’s strong market position is further supported by rising demand for meat and eggs, expanding commercial farming operations, and government initiatives to support the livestock sector. As a result, Asia Pacific continues to be the dominant force, with ongoing growth fueled by both economic development and evolving consumer preferences.

Leading Probiotics in Animal Feed Companies:

The report profiles key players such as Evonik Industries AG (Germany), ADM (US), DSM-Firmenich (Switzerland), Novonesis (Denmark), International Flavors & Fragrances Inc. (US), Alltech (US), Kemin (US), Land O’Lakes, Inc. (US), Orffa (Netherlands), Lallemand Inc. (Canada), Lesaffre (France), Church & Dwight Co., Inc (US), Phibro Animal Health Corporation (US), Sanzyme Biologics (India), and Virbac (France).

Recent Developments in the Probiotics in Animal Feed Industry:

  • In March 2025, IFF launched its Enviva PRO three-strain Bacillus probiotic for swine in order to better support piglet gut health at the critical point of weaning. The advent of the product, therefore, also dedicated an addition to IFF’s animal nutrition portfolio. It gave the company the opportunity to tap into the increased demand for effective science-based products within livestock while allowing swine producers to increase animal welfare, productivity, and profitability.
  • In March 2025, Orffa’s partnership with Florates strengthened its foothold in the probiotics in animal feed market by adding rapid, non-intrusive gut health diagnostics, giving producers access to live microbiome data for fast interventions, feed plan redesign, and improved animal outcomes, elevating Orffa’s part in delivering sustainable, data-based livestock management plans.

 

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/probiotics-animal-feed-market-85832335.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Probiotics in Animal Feed Market Size, Share, Growth Drivers, Opportunities, and Forecast Report (2025–2030)

Exosome Research Market worth US$480.6 million by 2030 with 17.5% CAGR | MarketsandMarkets™

“Key players in the exosome research market include Thermo Fisher Scientific, Inc. (US), Bio-Techne (US), System Biosciences, LLC (US), QIAGEN (Germany), Lonza (Switzerland), NX Pharmagen (US), NanoSomiX (US), Miltenyi Biotech (Germany), Norgen Biotek Corp. (Canada), AMSBio (UK), and Aethlon Medical, Inc. (US).”
Browse 391 market data Tables and 52 Figures spread through 324 Pages and in-depth TOC on “Exosome Research Market by Offering (Kits, Reagents (Antibodies, Isolation, Purification), Instruments, Services), Indication (Cancer, Infectious Diseases), Application (Biomarkers, Vaccines), Manufacturing Services (Stem Cell) – Global Forecast to 2030

The global Exosome Research Market, valued at US$189.4 million in 2024 stood at US$214.4 million in 2025 and is projected to advance at a resilient CAGR of 17.5% from 2025 to 2030, culminating in a forecasted valuation of US$480.6 million by the end of the period. The expansion of the exosome research market is primarily fueled by several key factors, including heightened investment in pharmaceutical & life sciences research, a growing incidence of cancer, and a rising interest in exosome-based methodologies for diagnostics and therapeutics. Nevertheless, the intricate technical challenges associated with exosome isolation and existing technological constraints are likely to impede the market’s growth trajectory.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=224782498

Browse in-depth TOC on “Exosome Research Market“

391 – Tables

52 – Figures

324 – Pages

By offering, in 2024, the kits and reagents sector emerged as the dominant market segment within the exosome research market, commanding the largest share. This growth can be attributed primarily to the escalating demand for advanced diagnostic solutions aimed at addressing chronic diseases such as cancer, neurodegenerative disorders like Alzheimer’s and Parkinson’s, and various cardiovascular conditions. These diseases have a significant impact on public health, driving the urgent need for innovative diagnostic tools that can enhance early detection and treatment efficacy. As research increasingly highlights the potential of exosomes in facilitating early diagnosis, ongoing patient monitoring, and personalized therapeutic approaches, there has been a corresponding surge in demand for reliable, high-quality tools for the isolation and analysis of exosomes. Exosomes are small extracellular vesicles that play a pivotal role in intercellular communication and have shown promise as biomarkers for various diseases. Moreover, the growing acceptance and integration of exosome-based applications within both clinical settings and research laboratories continue to catalyze the expansion of this crucial market segment. Researchers and clinicians are increasingly recognizing the value of exosomes not only for diagnostic purposes but also for their potential in therapeutic interventions. This trend underscores the necessity for sophisticated kits and reagents that can facilitate accurate isolation, characterization, and application of exosomes in a wide range of biomedical contexts. The convergence of these factors is significantly propelling the evolution of the kits and reagents sector within the exosome research market.

By Application, In the realm of global exosome research, biomarkers have established themselves as a leading segment, capturing the largest share of the market. This dominance is fueled by their increasingly pivotal role in the field of personalized medicine. Biomarkers are essential for the early detection of diseases, evaluating patient prognosis, and steering tailored therapeutic approaches, particularly in the contexts of cancer and chronic illnesses. Exosomes, which are tiny vesicles released by cells, are gaining recognition as exceptionally promising biomarkers due to their unique properties. They offer the ability to deliver real-time insights into the biological state of diseases, rendering them particularly valuable for applications in precision medicine. As ongoing research continues to unveil a growing array of exosome-based biomarkers, we can anticipate significant growth in this sector, coupled with a surge in investment as the medical community seeks to harness the vast potential of exosomes in enhancing patient care.

By geography, North America has emerged as the dominant region in the global exosome market, primarily due to a confluence of factors that foster an environment conducive to innovation and development. The region boasts a robust research infrastructure that supports cutting-edge biotechnology and pharmaceutical R&D. Significant financial investments from both private and public sectors have accelerated advancements in these fields, allowing for a more rapid pace of research and discovery. Furthermore, North America is home to numerous leading biopharmaceutical companies that are at the forefront of exosome research, alongside esteemed academic institutions renowned for their contributions to scientific knowledge and innovation. This collaboration between industry and academia has catalyzed a growing number of clinical trials that focus specifically on exosome-based therapies, thereby driving regional growth and setting the stage for future breakthroughs. The supportive regulatory frameworks also play a crucial role in facilitating the development and approval of novel exosome-related diagnostics and therapeutics. These frameworks not only streamline the pathway for bringing new products to market but also enhance investor confidence in the evolving landscape of personalized medicine and liquid biopsy diagnostics. Moreover, there is an increasing demand for personalized medicine approaches, which tailor treatment strategies to individual patient profiles, alongside the rising popularity of liquid biopsies that leverage exosomes for non-invasive diagnostics. This growing market demand underscores North America’s position as a key hub for innovation and commercialization in the exosome market, reflecting its critical role in shaping the future of biotechnology and healthcare.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=224782498

Key players in the exosome research market include Thermo Fisher Scientific, Inc. (US), Bio-Techne (US), System Biosciences, LLC (US), QIAGEN (Germany), Lonza (Switzerland), NX Pharmagen (US), NanoSomiX (US), Miltenyi Biotech (Germany), Norgen Biotek Corp. (Canada), AMSBio (UK), and Aethlon Medical, Inc. (US).

Thermo Fisher Scientific Inc. (US):

Thermo Fisher Scientific Inc. stands as a prominent entity within the exosome research market, offering an extensive portfolio that includes specialized kits, reagents, and custom exosome manufacturing services. The company demonstrates a robust commitment to R&D, allocating approximately USD 1.39 billion in R&D to advance its initiatives in 2024. Its strategic expansion encompasses R&D, manufacturing, sales, distribution, and administrative operations across more than 80 countries, significantly enhancing its competitive edge. In June 2023, Thermo Fisher introduced DynaGreen beads—innovative magnetic beads precoated with targeted proteins or antibodies specifically designed for the isolation of exosomes. This launch reflects Thermo Fisher’s strategic positioning within the exosome research arena, showcasing a dual focus on environmental sustainability and advancements in technological efficiency.

Bio-Techne (US)

Bio-Techne solidified its status as a significant player in the liquid biopsy diagnostics arena following its acquisition of Exosome Diagnostics in 2018; this strategic move allowed the company to enhance its product portfolio, offering a range of exosome diagnostic tests and equipment that align with emerging trends in the field. Bio-Techne aims to strengthen its competitive edge in the global exosome research market by focusing on innovative product launches. A notable example of this commitment is the recent introduction of a highly sensitive ESR1 mutation monitoring assay in December 2024. This research-use-only assay integrates a quantitative PCR (qPCR) detection kit and an isolation kit designed for cell-free DNA and exosomal RNA, reflecting the company’s dedication to advancing the capabilities of exosome-based diagnostics.

For more information, Inquire Now!

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/exosome-research-product-market-224782498.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Exosome Research Market worth US$480.6 million by 2030 with 17.5% CAGR | MarketsandMarkets™